Krensavage Asset Management, LLC Q3 2022 vs. Q4 2022 13F Holdings Comparison

As an investor, staying up-to-date on your portfolio is critical to ensuring that your assets are working effectively for you. One way to achieve this is by analyzing the 13F filings of your fund. This article will explore the changes in holdings of Krensavage Asset Management, LLC, between Q3 2022 and Q4 2022, and discuss what these changes may mean for the future of the fund.

Krensavage Asset Management, LLC is a hedge fund that primarily invests in the healthcare sector. In Q3 2022, the fund held shares in 14 companies, with a total value of $239,314,000. By the end of Q4 2022, the fund had reduced its holdings to 13 companies, with a total portfolio value of $242,262,000. Let's take a closer look at the individual holdings and changes that took place during this period.

The largest holding of the fund at the end of Q3 2022 was Alkermes Plc (ALKS), with 1,411,682 shares valued at $31,523,000. During the fourth quarter, the fund slightly reduced its position to 1,401,783 shares, which were valued at $36,629,000. This change represented an increase in value of 16.2%, making Alkermes the top performing position of the fund for the period.

The second-largest holding of the fund in Q3 2022 was Exelixis Inc (EXEL), with 1,821,475 shares valued at $28,561,000. By the end of Q4 2022, the fund had increased its position in Exelixis to 2,138,039 shares, which were valued at $34,294,000. This represented a growth of 20.1% in Exelixis' value, making it the second-best performing position of the fund for the period.

Another major holding of the fund is United Therapeutics Corp (UTHR). In Q3 2022, the fund held 200,407 shares of UTHR, with a total value of $41,961,000. By the end of Q4 2022, the fund had reduced its position to 192,048 shares, valued at $53,407,000. Despite the decrease in shares, UTHR's value increased by 27.3%, making it the top-performing stock of the fund for the period.

In comparison, Regeneron Pharmaceuticals (REGN) only experienced a slight increase in value during the period. The fund held 60,889 shares in the company with a total portfolio value of $41,945,000 in Q3 2022. By Q4 2022, the holdings decreased marginally to 60,103 shares, with a total portfolio value of $43,364,000, representing a growth of 3.4%.

On the other hand, Vanda Pharmaceuticals (VNDA) experienced a significant decline in value during the period. In Q3 2022, the fund held 312,299 shares in the company, with a total value of $3,086,000. However, by the end of Q4 2022, the fund's position had increased to 345,290 shares, but the value had decreased to $2,552,000, a decline of 17.3%.

In conclusion, Krensavage Asset Management, LLC made some notable changes to their portfolio between Q3 2022 and Q4 2022, with Alkermes Plc, Exelixis Inc, and United Therapeutics Corp emerging as the top-performing stocks for the period. While it is challenging to predict the future performance of these holdings, keeping an eye on these companies can provide valuable insights to investors looking to optimize their portfolio.